Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    BijnorNews
    Bijnor news

    Dr Reddy's Q1 Review: Brokerages Cut Targets After Q1 Miss; Weak US Business, Semaglutide Hit Key Triggers

    1 day ago

    Morgan Stanley, BofA and Citi cut target prices on Dr Reddy's after a weak Q1. Here's what they said about semaglutide, margins and H2 recovery.
    Click here to Read More
    Previous Article
    Who's Leading Fintech In 2026? These Indian Firms Shine In Digital Assets, Payments Among Global Best
    Next Article
    JSW Energy Q1 Review: Brokerages Stay Bullish Despite Q1 Profit Dip — Should You Buy?

    Related Business Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment